Dr. Reddy's Laboratories Limited (DRREDDY) — Financial Results
Dr. Reddy's Laboratories announced that its board will meet on July 22, 2026, to review unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The trading window for company securities will be closed from June 24, 2026, to July 24, 2026, inclusive, per SEBI insider trading regulations.
About Dr. Reddy's Laboratories Limited (DRREDDY)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Recent Announcements from Dr. Reddy's Laboratories Limited
-
🔴 Financial Results — 13 July 2026
Dr. Reddy's Laboratories announced it will release Q1FY27 results on Wednesday, July 22, 2026 after the board meeting, followed by an earnings call at... -
share transfer — 3 July 2026
Dr. Reddy's Laboratories disclosed a SEBI-mandated confirmation certificate from its share transfer agent, Bigshare Services Private Limited, covering... -
Announcement — 25 June 2026
Dr. Reddy's Laboratories announced that the USFDA completed a Pre-License Inspection at its Bachupally biologics facility in Hyderabad from June 16 to... -
🔴 Corporate Action — 19 June 2026
Dr. Reddy's Laboratories allotted 6,730 fully paid equity shares of Re.1 each to eligible employees on June 19, 2026, through exercise of stock option... -
Announcement — 13 June 2026
Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on Ju...
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when DRREDDY files new disclosures
Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DRREDDY — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research